Lack of survival improvement in patients with peripheral T-cell lymphoma: A Surveillance, Epidemiology, and End Results analysis

Leukemia and Lymphoma

Volumn 52, Issue 2, 2011, Pages 194-204

  Morgensztern, Daniel ^a   Walker, Gail R ^b   Koniaris, Leonidas G ^c   Lossos, Izidore S ^d  

^a USA   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c Department of Surgery ^*  (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Diffuse large B cell lymphoma; SEER; T cell lymphoma

Indexed keywords

RITUXIMAB;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; DEATH; EVOKED RESPONSE AUDIOMETRY; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PERIPHERAL T CELL LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; T CELL LYMPHOMA; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NEOPLASM STAGING; SEER PROGRAM; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 79551631846     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.542596     Document Type: Article

References (38)

1. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982;49: 2112-2135.
2. Harris N, Jaffe E, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392. (Pubitemid 24273002)
3. Cheng A, Chen Y, Wang C, et al. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades-should peripheral T-cell lymphoma be considered separately? J Clin Oncol 1989;7:725-731.
4. Kwak L, Wilson M, Weiss L, et al. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. J Clin Oncol 1991;9:1426-1431.
5. Melnyk A, Rodriguez A, Pugh W, Cabannillas F. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997;89: 4514-4520.
6. López-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 1998;9:849-855.
7. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998;92:76-82.
8. Morabito F, Gallamini A, Stelitano C, et al. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. Cancer 2004;101:1601-1608.
9. Savage K, Chhanabhai M, Gascoyne R, Connors J. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004;15:1467-1475.
10. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non- Hodgkin's Lymphoma Classification Project. Blood 1997;89: 3909-3918.
11. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiological research from the pathology working group of the international lymphoma epidemiology consortium (InterLymph). Blood 2007;110: 695-708.
12. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti- CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-1932.
13. Pintilie M. Competing risks: a practical perspective. Chichester, UK: John Wiley & Sons; 2006.
14. Collett D. Modeling survival data in medical research. 2nd ed. New York: CRC Press; 2003.
15. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16: 1141-1154.
16. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94: 496-509.
17. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. Hoboken, NJ: John Wiley & Sons; 2002.
18. The R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2009. Available from:
19. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-4130.
20. McLaughlin P, Grillo-López A, Link B, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
21. Fisher R, Gaynor E, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
22. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
23. Habermann T, Weller E, Morrison V, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127.
24. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large- B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
25. Haioun C, Lepage E, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. J Clin Oncol 1997;15:1131-1137.
26. Santini G, Salvagno L, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative group. J Clin Oncol 1998;16:2796-2802.
27. Kaiser U, Uebelacker I, Abel U, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for 'aggressive' lymphoma. J Clin Oncol 2002;20: 4413-4419.
28. Martelli M, Gherlinzoni F, De Renzo A, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol 2003;21:1255-1262.
29. Dunleavy K, Mikhaeel G, Sehn LH, et al. The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. Leuk Lymphoma 2010;51(Suppl. 1):28-33.
30. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27:1906-1914.
31. Escalón M, Liu N, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005;103: 2091-2098.
32. Corradini P, Tarella C, Zallio F, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20:1533-1538.
33. Rodríguez J, Munsell M, Salim Y, et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001;19:3766-3770.
34. Mercadal S, Briones J, Xicoy B, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008;19:958-963.
35. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath- 1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007;110:2316-2323.
36. Sehn L, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-5033.
37. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-276.
38. Bradford PT, Devessa SS, Anderson WF, et al. Cutaneous lymphoma incidence patterns in the United States: a population- based study of 3884 cases. Blood 2009;113:5064-5073.